Novartis announced FDA approval for Fabhalta
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- S&P 500, Dow at record highs as Mideast hopes offset SpaceX, AMD drag
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
December 6, 2023 12:19 AM ESTApproval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5 In APPLY-PNH, patients who switched to Fabhalta experienced superior increases of hemoglobin levels 2 g/dL (82.3% vs. 0%) and hemoglobin level 12 g/dL (67.7% vs. 0%), both in the absence of red blood cell transfusions, vs. patients who continued on anti-C5 treatment1,2 Fabhalta, now available for both previously treated and treatment-naïve patients, is the only FDA-approved Factor B inhibitor of the... More
